Class I Antiarrhythmics: Sodium Channel Blockers

Class I antiarrhythmic drugs block the fast voltage-gated sodium channels responsible for the rapid upstroke (phase 0) of the cardiac action potential. By slowing the rate of depolarization they slow impulse conduction through atrial, ventricular and His-Purkinje tissue. The class is traditionally divided into subclasses IA, IB and IC according to the strength of sodium block and the accompanying effect on action-potential duration.

Definition

Class I antiarrhythmics are sodium channel blockers that reduce the maximum rate of phase-0 depolarization of the cardiac action potential, thereby slowing conduction; they are subdivided into IA, IB and IC by the degree of block and their effect on action-potential duration.

Scope

The entry covers the electrophysiology of cardiac sodium channel block, the IA/IB/IC subdivision and how each subclass differs in binding kinetics and effect on repolarization, the concept of use dependence, and the proarrhythmic risk that defines the clinical caution around this class. It is a reference topic within antiarrhythmic pharmacology and provides no dosing or treatment instructions.

Key concepts

• Fast sodium current (phase 0 depolarization)
• Subclasses IA, IB and IC
• Use dependence (state-dependent channel block)
• Effect on action-potential duration and refractoriness
• Conduction slowing
• Proarrhythmia and the CAST lesson

Mechanisms

Class I agents bind voltage-gated cardiac sodium channels preferentially in the open or inactivated state, reducing the inward sodium current that drives phase 0 and thereby slowing conduction velocity. The block is use-dependent: it intensifies at faster heart rates when channels cycle more often through the states the drug binds. Subclasses differ in binding kinetics and repolarization effects — IA agents show intermediate dissociation kinetics and prolong the action potential, IB agents bind and dissociate rapidly and shorten or minimally change it, and IC agents dissociate slowly, producing marked conduction slowing with little change in action-potential duration. These differences underlie the distinct electrophysiological profiles described in classification reviews.

Clinical relevance

Class I drugs illustrate both the rationale and the hazards of antiarrhythmic therapy. The CAST trial showed that suppressing post-infarction ventricular ectopy with class IC agents increased mortality, and contemporary guidance accordingly restricts the use of class I agents in patients with structural heart disease. This entry describes mechanisms and trial evidence for reference and is not a basis for individual prescribing decisions.

Evidence & guidelines

The CAST trial is the defining evidence for this class, demonstrating excess mortality with encainide and flecainide used to suppress ventricular ectopy after myocardial infarction. Current rhythm-management guidance, such as the 2020 ESC atrial fibrillation guidelines, situates class I agents within rhythm-control strategies while cautioning against their use in the presence of structural or ischaemic heart disease.

History

Sodium channel block was the first mechanism recognized in the Vaughan Williams scheme, with quinidine-like agents as the prototype. The IA/IB/IC subdivision was introduced to separate agents with differing kinetics and repolarization effects. The 1989 CAST trial transformed clinical understanding by showing that class IC suppression of ectopy worsened survival, and the Sicilian Gambit and later modernized classifications refined the mechanistic picture of sodium-channel-acting drugs.

Debates

Is the IA/IB/IC subdivision mechanistically adequate?

The three-way split captures broad kinetic and repolarization differences, but agents within a subclass can differ in additional channel and receptor actions; modernized classifications argue for describing drugs by their full target profile rather than subclass alone.

Key figures

• Miles Vaughan Williams
• Bramah N. Singh

Seminal works

• cast-1989
• vaughan-williams-sicilian-1991
• lei-2018

Frequently asked questions

What distinguishes class IA, IB and IC antiarrhythmics?

All three block cardiac sodium channels, but they differ in binding kinetics and effect on the action potential: IA agents prolong it, IB agents shorten or minimally change it, and IC agents slow conduction strongly with little change in action-potential duration.

What is use dependence?

Use dependence means the degree of sodium channel block increases at faster heart rates, because the drug binds channels more effectively when they are cycling rapidly through the open and inactivated states it targets.